Clinical trial · Interventional
Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative Cancer
A Phase II Randomized Study to Assess the Benefit of a Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative Cancer
NCT00420563CI-TRIAL-00105585PALANGIcompletedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 18, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260918-000001
Summary
Brief summary (as posted)
The scope of the trial is to assess the free progression rate at 2 months for each group of patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CYCLOPHOSPHAMIDE | Drug | Cyclophosphamide | ALIAS |
| MEGESTROL | Drug | Megestrol | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- CYCLOPHOSPHAMIDE
- interventionNames
- Drug: CYCLOPHOSPHAMIDE
- type
- ACTIVE_COMPARATOR
- label
- MEGESTROL
- interventionNames
- Drug: MEGESTROL
Primary outcomes (1)
- measure
- Progression free survival rate at 2 months
- timeFrame
- 2 months
Secondary outcomes (5)
- measure
- Progression free survival rate and objective response (RECIST) at 2, 4 and 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> or = 18 * PS-WHO \< or = 1 * Histologically proven cancer * No other therapeutic proposal * Treatment can be orally taken * Radiologic proof of evolutive character of the disease * Effective contraception Exclusion Criteria: * Hypercalcemia ( Ca \> 2.65 mmol/l) * Breast cancer * Thrombosis or pulmonary embolism * Dysphagia, malabsorption * Polynuclear neutrophil leukocytes \< 1000/mm3 * Treatment with Tegretol * Active and uncontrolled infection * Evolutive psychiatric disease * Pregnant or lactating woman
References
Publications (0)
Data not yet available
No reference posted for this study.